3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Pain
4
Pain, Postoperative
3
Agnosia
3
Ovarian Neoplasms
2
Inflammation
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Thyroid Nodule
1
Reperfusion Injury
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Obesity
1
Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Ileus
1
Goiter
1
End Stage Liver Disease
1
Emergencies
1
Diverticulosis, Colonic
1
Diverticulitis, Colonic
1
Curative Breast Cancer Surgery
1
Constipation
1
Interventions
Exercise
24
Metformin
19
Tirzepatide
9
Resistance Training
8
Nutrition Assessment
8
Methods
8
Diet Therapy
8
Diet
8
Counseling
7
Surveys and Questionnaires
6
semaglutide
5
Liraglutide
5
Exenatide
5
Early Intervention, Educational
5
Diet, Mediterranean
5
Caloric Restriction
5
Blood Specimen Collection
5
Educational Status
4
Bariatric Surgery
4
Vitamin D
3
Sugars
3
Standard of Care
3
Naltrexone
3
Letrozole
3
Docosahexaenoic Acids
3
Dexamethasone
3
Bupropion
3
exemestane
2
bupropion hydrochloride, naltrexone hydrochoride drug combination
2
Yoga
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Obesity
×
Ketorolac
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled